Holen Sie sich die Stockscreener-App
0.28
1.08%
0.003
Handel nachbörslich:
.28
Schlusskurs vom Vortag:
$0.277
Offen:
$0.286
24-Stunden-Volumen:
136.38K
Relative Volume:
0.03
Marktkapitalisierung:
$2.08M
Einnahmen:
$79,300
Nettoeinkommen (Verlust:
$-6.92M
KGV:
-0.0148
EPS:
-18.9818
Netto-Cashflow:
$-5.34M
1W Leistung:
-2.10%
1M Leistung:
-22.01%
6M Leistung:
-71.69%
1J Leistung:
-86.47%
1-Tages-Spanne:
$0.27
$0.2899
1-Wochen-Bereich:
$0.255
$0.305
52-Wochen-Spanne:
$0.255
$2.29
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Firmenname
Virax Biolabs Group Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie VRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
0.28 | 2.06M | 79,300 | -6.92M | -5.34M | -18.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-31 | Eingeleitet | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd Aktie (VRAX) Neueste Nachrichten
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Exit Recap: Should I average down on PodcastOne Inc stockGap Down & Smart Investment Allocation Insights - baoquankhu1.vn
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Virax Biolabs Group (NASDAQ:VRAX) Upgraded at Zacks Research - Defense World
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why - Yahoo Finance
Virax Biolabs stock price target lowered to $1 at H.C. Wainwright By Investing.com - Investing.com South Africa
Virax Biolabs stock price target lowered to $1 at H.C. Wainwright - Investing.com India
Virax Biolabs secures $5 million in private placement to advance immunology research - MSN
HC Wainwright Reaffirms “Buy” Rating for Virax Biolabs Group (NASDAQ:VRAX) - Defense World
Virax Biolabs: Clinical Progress in PAIS and Extended Cash Runway Support Reiterated Buy Rating Despite Lowered Price Target - TipRanks
VRAX Analyst Forecasts - Quiver Quantitative
Why Virax Biolabs Group Limited stock is favored by top institutions - Улправда
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Wondering what's happening in today's after-hours session? - Chartmill
Virax Biolabs Releases Interim Financial Results for September 2025 - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Is Virax Biolabs Group Limited stock positioned for long term growthJuly 2025 Update & Real-Time Market Trend Scan - Улправда
Can Virax Biolabs Group Limited stock beat market expectations this quarterWeekly Market Outlook & Real-Time Sentiment Analysis - Улправда
Virax Biolabs (NASDAQ: VRAX) details 25.9M-share resale from $5M raise - Stock Titan
Virax Biolabs Group (NASDAQ:VRAX) Shares Down 11.3% – Here’s Why - Defense World
A new trading data show Virax Biolabs Group Ltd (VRAX) is showing positive returns. - Setenews
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Penny Stocks To Keep An Eye OnDecember 3rd - MarketBeat
Why Virax Biolabs Group Limited stock is seen as undervalued2025 Geopolitical Influence & Detailed Earnings Play Alerts - Newser
Virax Biolabs Secures $5 Million in Private Placement to Advance Immunology Research - The Globe and Mail
Virax Biolabs (Nasdaq: VRAX) closes $5 million raise, cash runway into 2028 - Stock Titan
US Market Preview | VRAX Surges 108.0%; ADP Jobs Data Misses Expectations, Futures Rise; NVDA's OpenAI Investment Pending - Sahm
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Healthy Upside Potential: Transocean Ltd (RIG) - Setenews
Ready to Jump After Recent Trade: Virax Biolabs Group Ltd (VRAX) - setenews.com
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Virax Biolabs (VRAX) Stock Cools After Hours Following 75% Rally - Benzinga
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.86% - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 0.86% By Investing.com - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.86% - Investing.com
Scienjoy (NASDAQ: SJ): Deep-Value, Cash-Rich Tech with Mixed-Reality Upside More Inside - openPR.com
Virax Biolabs Group Limited (VRAX) Stock: Surges as 2026 Strategy and Clinical Milestones Ignite Investor Interest - parameter.io
Virax Biolabs : Announces $5 Million Private Placement - marketscreener.com
Virax Biolabs (Nasdaq: VRAX) announces $5 million private placement for working capital - Stock Titan
Crude Oil Gains 1%; Macy's Reports Strong Q3 Results - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BC-Most Active Stocks - Yahoo Finance
Ming Shing Group (NASDAQ: MSW) adds Tianhang Zhao to Board, audit chair named - Stock Titan
US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - Benzinga
Virax Biolabs stock rockets after clinical progress in post-infection diagnostics By Investing.com - Investing.com South Africa
Virax Biolabs stock rockets after clinical progress in post-infection diagnostics - Investing.com India
Credo Technology Group (NASDAQ: CRDO) to present at Barclays 23rd Global Technology Conference on Dec. 10 - Stock Titan
The LGL Group (NYSE American: LGL) moves warrant deadline from Dec. 9 to Dec. 16, 2025 - Stock Titan
Nu Holdings (NYSE: NU) to add Brazil banking license without changing Nubank brand - Stock Titan
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PR Newswire
Finanzdaten der Virax Biolabs Group Ltd-Aktie (VRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):